Source-grounded facts extracted from AXIM BIOTECHNOLOGIES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Catalina Valencia was appointed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
“effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy”
Catalina Valencia was appointed as President at AXIM BIOTECHNOLOGIES, INC..
“on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.”
John W. Huemoeller II departed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
“On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.”
John W. Huemoeller II departed as President and CEO at AXIM BIOTECHNOLOGIES, INC..
“Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness”
AXIM BIOTECHNOLOGIES, INC. incurred convertible notes of $814,555 at 4.25% annually maturing March 1, 2034.
“On March 15, 2024, the Company issued unsecured convertible notes with an aggregate face value of $814,555 as more fully described in Item 1.01 above, which is incorporated by reference thereto.”
AXIM BIOTECHNOLOGIES, INC. entered into a notes offering with its independent directors, certain officers and contractors of the Company, and employees of its wholly-owned subsidiary, Sapphire Biotech, Inc. valued at aggregate face value of $814,555 (effective 2024-03-15).
“On March 15, 2024, AXIM Biotechnologies, Inc. (the “Company”) issued Convertible Notes, having an aggregate face value of $814,555 (the "Notes"), to (i) its independent directors for past due director fees, (ii) certain officers and contractors of the Company for past due salaries and fees for services rendered, and (iii) employees of its wholly-owned subsidiary, Sapphire Biotech, Inc. ("Sapphire"), for past due salaries.”
AXIM BIOTECHNOLOGIES, INC. entered into Settlement Agreement with Innovative Medical Supplies, LLC (effective 2024-02-07).
“Effective February 7, 2024, the Company entered into a confidential Global Settlement Agreement and Mutual Release (the “Settlement Agreement”) to resolve the IMS Action as well as a second related action involving many of the same parties.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.